Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback